Open AccessHigh SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer
Author(s) -
Chotaro Onaga,
Shoma Tamori,
Izumi Matsuoka,
Ayaka Ozaki,
Hitomi Motomura,
Yuka Nagashima,
Tsugumichi Sato,
Keiko Sato,
KOUJI TAHATA,
Yuyun Xiong,
YOSHIO NAKANO,
Yasunari Mano,
SATORU MIYAZAKI,
Kazunori Sasaki,
Shigeo Ohno,
Kazunori Akimoto
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10126
Subject(s) - radiation therapy , breast cancer , estrogen receptor , oncology , medicine , estrogen , cancer , cancer research
Radiotherapy is one of the main treatments for estrogen receptor-positive (ER+) breast cancer. However, in some ER+ breast cancer cases, radiotherapy is insufficient to inhibit progression and there is a lack of markers to predict radiotherapy insensitivity. Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been proposed to be a viable prognostic marker for luminal A and B types of ER+ breast cancer. The present study examined the possibility of SLC20A1 as a novel biomarker for the prediction of radiotherapy efficiency.